Breadcrumb

CL3 homepage banner

Containment Level 3

Containment Level 3 Containment Level 3

Containment Level 3 (CL3) Platform homepage

A state-of-the-art, multipod facility for studies of tuberculosis, influenza and human immunodeficiency virus (HIV)

The Containment Level 3 (CL3) Platform has three independent pods that meet the highest safety standards defined by Canadian Biosafety Standards and Guidelines (PHAC and CFIA).

The facility is available to RI-MUHC researchers, affiliated collaborators and external researchers whose work requires a facility where properly trained users can manipulate various pathogenic organisms.

Users of the CL3 Platform must follow the established Standard Operating Procedures (SOPs), as defined in the platform’s SOP manual.

Director: Marcel Behr, MD, M.Sc.
Platform Manager: Fiona McIntosh, B.Sc.
Click here to contact us

 

Platform News and Events

News and Events

Asset Publisher

Paving the way for COVID-19 research

RI-MUHC and McGill Containment level 3 Labs receive $1M in funding to accelerate research with live SARS Cov-2

Containment Level 3 facilities advance COVID-19 research at the RI-MUHC and McGill

Infrastructure to study COVID-19 in a secure environment is creating new possibilities for collaboration and discovery